STOCK TITAN

United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 and acquired 9,500 common shares on July 27, 2026. Those shares were then sold in multiple trades totaling 9,500 shares at prices between about $526 and $535 per share under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. Following the exercise, a trust reports 265,410 options remaining, as part of up to 1,734,410 options covered by the plan and expiring March 15, 2027, while separate entries show 40,513 shares held directly and 166 shares held indirectly by spouse.

Positive

  • None.

Negative

  • None.
Insider ROTHBLATT MARTINE A
Role Chairperson & CEO
Sold 9,500 shs ($5.04M)
Approx. gross sale proceeds $5.04M
Approx. exercise cost $1.29M
Approx. pre-tax spread $3.75M
Type Security Shares Price Value
Exercise Stock Option F1, F14 9,500 $0.00 $0.00
Exercise Common Stock F1, F2 9,500 $135.42 $1.29M
Sale Common Stock F1, F3, F2 680 $525.8111 $358K
Sale Common Stock F1, F4, F2 890 $527.1376 $469K
Sale Common Stock F1, F5, F2 650 $528.507 $344K
Sale Common Stock F1, F6, F2 1,797 $529.7493 $952K
Sale Common Stock F1, F7, F2 1,121 $530.4861 $595K
Sale Common Stock F1, F8, F2 1,836 $531.6488 $976K
Sale Common Stock F1, F9, F2 1,529 $532.377 $814K
Sale Common Stock F1, F10, F2 957 $533.5314 $511K
Sale Common Stock F1, F2 40 $535.04 $21K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock F11 -- -- --
holding Common Stock F12 -- -- --
holding Common Stock F13 -- -- --
Holdings After Transaction: Stock Option — 265,410 shares (Indirect, by Trust); Common Stock — 628,049 shares (Indirect, by Trust); Common Stock — 40,513 shares (Direct); Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (14)
  1. F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
  2. F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
  3. F3. This transaction was executed in multiple trades at prices ranging from $525.62 to $526.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F4. This transaction was executed in multiple trades at prices ranging from $526.96 to $527.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. F5. This transaction was executed in multiple trades at prices ranging from $527.96 to $528.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. F6. This transaction was executed in multiple trades at prices ranging from $529.05 to $530.045. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. F7. This transaction was executed in multiple trades at prices ranging from $530.05 to $531.01 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. F8. This transaction was executed in multiple trades at prices ranging from $531.08 to $532.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. F9. This transaction was executed in multiple trades at prices ranging from $532.08 to $533.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. F10. This transaction was executed in multiple trades at prices ranging from $533.13 to $534.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  11. F11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
  12. F12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
  13. F13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
  14. F14. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Options exercised 9,500 options Stock options exercised on July 27, 2026 at $135.4200 per share
Shares sold 9,500 shares Total common shares sold in multiple transactions on July 27, 2026
Example sale price $525.8111 per share Weighted average price for a 680-share sale tranche on July 27, 2026
Remaining options in trust 265,410 options Stock options held by a family trust following the reported option exercise
Direct share holdings 40,513 shares Common shares held directly by the reporting person as of July 27, 2026
Spouse indirect holdings 166 shares Common shares held indirectly through the reporting person’s spouse
10b5-1 plan option capacity 1,734,410 options Maximum stock options whose exercise is contemplated under the trading plan
10b5-1 plan latest end date December 31, 2026 Latest termination date for the pre-arranged trading plan
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"transaction was executed in multiple trades at prices ranging from $525.62 to $526.36. The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"exercise of 1,734,410 stock options, all of which expire on March 15, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
derivative security financial
"transaction code description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did United Therapeutics (UTHR) report for Martine A. Rothblatt?

On July 27, 2026, Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $135.42 into 9,500 common shares, then sold all 9,500 shares in multiple transactions executed through family trusts under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the UTHR shares sold in the reported insider transactions?

The 9,500 United Therapeutics shares were sold in several tranches at per-share prices generally around the low $530s, including 680 shares at a weighted average price of $525.8111 and a final 40-share sale at $535.0400 per share.

Was the UTHR CEO’s trading activity carried out under a Rule 10b5-1 plan?

Yes. The exercise of options and sale of resulting UTHR shares occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of exercising 1,734,410 options or December 31, 2026.

How many options and shares does the UTHR CEO report holding after these trades?

After the reported exercise, a family trust holds 265,410 stock options expiring March 15, 2027. Separate holding entries list 40,513 UTHR shares held directly by the reporting person and 166 shares held indirectly through the CEO’s spouse, plus additional holdings via family trusts.

How are family trusts involved in the UTHR insider transactions and holdings?

Both the option exercise and share sales were executed through family trusts. Footnotes state these trusts are entities where the reporting person or spouse shares investment power or serves as trustee, and the reporting person and/or immediate family members are beneficiaries of the trusts.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROTHBLATT MARTINE A

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairperson & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/27/2026M(1)9,500A$135.42333,943Iby Trust(2)
Common Stock07/27/2026S(1)680D$525.8111(3)333,263Iby Trust(2)
Common Stock07/27/2026S(1)890D$527.1376(4)332,373Iby Trust(2)
Common Stock07/27/2026S(1)650D$528.507(5)331,723Iby Trust(2)
Common Stock07/27/2026S(1)1,797D$529.7493(6)329,926Iby Trust(2)
Common Stock07/27/2026S(1)1,121D$530.4861(7)328,805Iby Trust(2)
Common Stock07/27/2026S(1)1,836D$531.6488(8)326,969Iby Trust(2)
Common Stock07/27/2026S(1)1,529D$532.377(9)325,440Iby Trust(2)
Common Stock07/27/2026S(1)957D$533.5314(10)324,483Iby Trust(2)
Common Stock07/27/2026S(1)40D$535.04324,443Iby Trust(2)
Common Stock40,513D
Common Stock166Iby Spouse
Common Stock249,108Iby Trust(11)
Common Stock45,596Iby Trust(12)
Common Stock8,902Iby Trust(13)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$135.4207/27/2026M(1)9,50003/15/202303/15/2027Common Stock9,500$0.00265,410Iby Trust(14)
Explanation of Responses:
1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
3. This transaction was executed in multiple trades at prices ranging from $525.62 to $526.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $526.96 to $527.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $527.96 to $528.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $529.05 to $530.045. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $530.05 to $531.01 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $531.08 to $532.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $532.08 to $533.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $533.13 to $534.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
14. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)